Sign in or Register   Sign in or Register
  |  

Mouse Anti-CD55 Recombinant Antibody (1D7) (CBMAB-C3858-LY)

This product is antibody recognizes CD55. The antibody 1D7 immunoassay techniques such as: ELISA, IF, WB.
See all CD55 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
1D7
Antibody Isotype
IgG1, κ
Application
ELISA, IF, WB

Basic Information

Immunogen
DAF (NP_000565, 35 a.a. ~ 134 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.Immunogen sequence: DCGLPPDVPN AQPALEGRTS FPEDTVITYK CEESFVKIPG EKDSVICLRG SQWSDIEEFC NRSCEVPTRL NSASLKQPYI TQNYFPVGTV VEYECRPGYR
Specificity
Human
Antibody Isotype
IgG1, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
CD55 Molecule (Cromer Blood Group)
Introduction
CD55 (CD55 Molecule (Cromer Blood Group)) is a Protein Coding gene. Diseases associated with CD55 include Complement Hyperactivation, Angiopathic Thrombosis, And Protein-Losing Enteropathy and Blood Group, Cromer System. Among its related pathways are Creation of C4 and C2 activators and Transport to the Golgi and subsequent modification.
Gene Ontology (GO) annotations related to this gene include lipid binding and virus receptor activity.
An important paralog of this gene is C4BPA.
Entrez Gene ID
UniProt ID
Alternative Names
CD55 Molecule (Cromer Blood Group); CD55 Molecule, Decay Accelerating Factor For Complement (Cromer Blood Group); CD55 Antigen; DAF; CR; Decay Accelerating Factor For Complement (CD55, Cromer Blood Group System);
Function
This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade (PubMed:7525274).
Inhibits complement activation by destabilizing and preventing the formation of C3 and C5 convertases, which prevents complement damage (PubMed:28657829).
(Microbial infection) Acts as a receptor for Coxsackievirus A21, coxsackieviruses B1, B3 and B5.
(Microbial infection) Acts as a receptor for Human enterovirus 70 and D68 (Probable).
(Microbial infection) Acts as a receptor for Human echoviruses 6, 7, 11, 12, 20 and 21.
Biological Process
Complement activation, classical pathway Source: UniProtKB-KW
Endoplasmic reticulum to Golgi vesicle-mediated transport Source: Reactome
Innate immune response Source: UniProtKB-KW
Negative regulation of complement activation Source: UniProtKB
Neutrophil degranulation Source: Reactome
Positive regulation of CD4-positive, alpha-beta T cell activation Source: UniProtKB
Positive regulation of CD4-positive, alpha-beta T cell proliferation Source: UniProtKB
Positive regulation of cytosolic calcium ion concentration Source: UniProtKB
Positive regulation of T cell cytokine production Source: UniProtKB
Regulation of complement activation Source: MGI
Regulation of complement-dependent cytotoxicity Source: MGI
Regulation of lipopolysaccharide-mediated signaling pathway Source: UniProtKB
Respiratory burst Source: UniProtKB
Cellular Location
Isoform 1&2&6&7: Cell membrane
Isoform 3&4&5: Secreted
Involvement in disease
Complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE): An autosomal recessive disease characterized by abdominal pain and diarrhea, primary intestinal lymphangiectasia, edema due to hypoproteinemia, malabsorption, and less frequently, bowel inflammation, recurrent infections, and angiopathic thromboembolic disease. Patients' T lymphocytes show increased complement activation causing surface deposition of complement and the generation of soluble C5a.
PTM
The Ser/Thr-rich domain is heavily O-glycosylated.

Moreira, M., Ruggiero, A., Iaccarino, E., Barra, G., Sandomenico, A., Ruvo, M., & Berisio, R. (2021). A structure-based approach for the development of a bicyclic peptide acting as a miniaturized anti-CD55 antibody. International Journal of Biological Macromolecules, 182, 1455-1462.

Niu, M., Xu, S., Yang, J., Yao, D., Li, N., Yan, J., ... & Song, G. (2021). Structural basis for CD97 recognition of the decay-accelerating factor CD55 suggests mechanosensitive activation of adhesion GPCRs. Journal of Biological Chemistry, 296.

Lin, W. D., Fan, T. C., Hung, J. T., Yeo, H. L., Wang, S. H., Kuo, C. W., ... & Alice, L. Y. (2020). Sialylation of CD55 by ST3GAL1 facilitates immune evasion in cancer. Cancer Immunology Research.

Pérez‐Alós, L., Bayarri‐Olmos, R., Skjoedt, M. O., & Garred, P. (2019). Combining MAP‐1: CD35 or MAP‐1: CD55 fusion proteins with pattern‐recognition molecules as novel targeted modulators of the complement cascade. The FASEB Journal, 33(11), 12723-12734.

Musarrat, T. (2019). Modulation of IL-10 production by CD3/CD55 induced Type 1 regulatory (Tr1) T-cells (Doctoral dissertation, University of Nottingham).

Loniewska‐Lwowska, A., Koza, K., Mendek‐Czajkowska, E., Wieszczy, P., Adamowicz‐Salach, A., Branicka, K., ... & Fabijanska‐Mitek, J. (2018). Diminished presentation of complement regulatory protein CD 55 on red blood cells from patients with hereditary haemolytic anaemias. International journal of laboratory hematology, 40(2), 128-135.

Dho, S. H., Lim, J. C., & Kim, L. K. (2018). Beyond the role of CD55 as a complement component. Immune network, 18(1).

Li, G., Yin, Q., Ji, H., Wang, Y., Liu, H., Jiang, L., ... & Li, B. (2018). A study on screening and antitumor effect of CD55-specific ligand peptide in cervical cancer cells. Drug design, development and therapy, 12, 3899.

Ozen, A., Comrie, W. A., Ardy, R. C., Domínguez Conde, C., Dalgic, B., Beser, Ö. F., ... & Lenardo, M. J. (2017). CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis. New England Journal of Medicine, 377(1), 52-61.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-CD55 Recombinant Antibody (1D7)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare